Neoadjuvant chemotherapy: are we barking up the right tree?

被引：9

作者：

Debled, M. ^{[1
]}

Mauriac, L. ^{[1
]}

机构：

[1] Reg Canc Ctr, Inst Bergonie, Dept Med Oncol, Bordeaux, France

来源：

ANNALS OF ONCOLOGY | 2010年 / 21卷 / 04期

关键词：

OPERABLE BREAST-CANCER; PATHOLOGICAL COMPLETE RESPONSE; EPIRUBICIN PLUS DOCETAXEL; COLONY-STIMULATING FACTOR; III RANDOMIZED GEPARTRIO; PHASE-III; PREOPERATIVE CHEMOTHERAPY; SYSTEMIC THERAPY; RESIDUAL DISEASE; CYCLES;

D O I：

10.1093/annonc/mdq062

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

引用

页码：675 / 679

页数：5

共 38 条

[1]

Amat S, 2002, INT J ONCOL, V20, P791

[2] A simple meta-analytic approach for using a binary surrogate endpoint to predict the effect of intervention on true endpoint [J].

Baker, SG .

BIOSTATISTICS, 2006, 7 (01) :58-70

[3] Accelerated versus standard cyclophosphamide, epirubicin and 5-fluorouracil or cyclophosphamide, methotrexate and 5-fluorouracil: a randomized phase III trial in locally advanced breast cancer [J].

Baldini, E ;

Gardin, G ;

Giannessi, PG ;

Evangelista, G ;

Roncella, M ;

Prochilo, T ;

Collecchi, P ;

Rosso, R ;

Lionetto, R ;

Bruzzi, P ;

Mosca, F ;

Conte, PF .

ANNALS OF ONCOLOGY, 2003, 14 (02) :227-232

[4] Sequential preoperative or postoperative docetaxel added to preoperative doxorubicin plus cyclophosphamide for operable breast cancer: National Surgical Adjuvant Breast and Bowel Project Protocol B-27 [J].

Bear, HD ;

Anderson, S ;

Smith, RE ;

Geyer, CE ;

Mamounas, EP ;

Fisher, B ;

Brown, AM ;

Robidoux, A ;

Margolese, R ;

Kahlenberg, MS ;

Paik, S ;

Soran, A ;

Wickerham, DL ;

Wolmark, N .

JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (13) :2019-2027

[5] 'Small' randomised neo-adjuvant chemotherapy trials in breast cancer reporting on pathological response: more harm than good? [J].

Bonnefoi, H .

ANNALS OF ONCOLOGY, 2005, 16 (09) :1407-1410

[6]

Buyse M, 2000, Biostatistics, V1, P49, DOI 10.1093/biostatistics/1.1.49

[7] Prospective evaluation of paclitaxel versus combination chemotherapy with fluorouracil, doxorubicin, and cyclophosphamide as neoadjuvant therapy in patients with operable breast cancer [J].

Buzdar, AU ;

Singletary, SE ;

Theriault, RL ;

Booser, DJ ;

Valero, V ;

Ibrahim, N ;

Smith, TL ;

Asmar, L ;

Frye, D ;

Manuel, N ;

Kau, SW ;

McNeese, M ;

Strom, E ;

Hunt, K ;

Ames, F ;

Hortobagyi, GN .

JOURNAL OF CLINICAL ONCOLOGY, 1999, 17 (11) :3412-3417

[8] A new prognostic classification after primary chemotherapy for breast cancer: Residual disease in breast and nodes (RDBN) [J].

Chollet, Philippe ;

Abrial, Catherine ;

Durando, Xavier ;

Thivat, Emilie ;

Tacca, Olivier ;

Mouret-Reynier, Marie-Ange ;

Leheurteur, Marianne ;

Kwiatkowski, Fabrice ;

Dauplat, Jacques ;

Penault-Llorca, Frederique .

CANCER JOURNAL, 2008, 14 (02) :128-132

[9] Neoadjuvant vinorelbine/epirubicin (VE) versus standard adriamycin/cyclophosphamide (AC) in operable breast cancer: analysis of response and tolerability in a randomised phase III trial (TOPIC 2) [J].

Chua, S ;

Smith, IE ;

A'Hern, RP ;

Coombes, GA ;

Hickish, TF ;

Robinson, AC ;

Laing, RW ;

O'Brien, MER ;

Ebbs, SR ;

Hong, A ;

Wardley, A ;

Mughal, T ;

Verrill, M ;

Dubois, D ;

Bliss, JM .

ANNALS OF ONCOLOGY, 2005, 16 (09) :1435-1441

[10] Phase III randomized trial of doxorubicin and docetaxel versus doxorubicin and cyclophosphamide as primary medical therapy in women with breast cancer: An anglo-celtic cooperative oncology group study [J].

Evans, TRJ ;

Yellowlees, A ;

Foster, E ;

Earl, H ;

Cameron, DA ;

Hutcheon, AW ;

Coleman, RE ;

Perren, T ;

Gallagher, CJ ;

Quigley, M ;

Crown, J ;

Jones, AL ;

Highley, M ;

Robert, LMH ;

Mansi, JL .

JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (13) :2988-2995

← 1 2 3 4 →